Core Insights - The company achieved total product revenue of approximately RMB 11.9 billion in 2025, marking a strong year-on-year growth of about 45% [1] - In Q4 2025, the company recorded total product revenue of approximately RMB 3.3 billion, with a year-on-year increase of over 60%, driven by the inclusion of six new drugs in the 2026 National Medical Insurance Directory [1] Group 1 - 2025 marked a milestone year for the company as product revenue surpassed RMB 10 billion, reflecting the successful implementation of its "dual-driven and global innovation" strategy [2] - The company has strengthened its leading position in the oncology treatment sector, expanding its oncology product portfolio to 13 products, with core products like Darbeshou (Sintilimab injection) showing steady growth [2] - The company has successfully ventured into the chronic disease commercialization field, leveraging unmet needs and strong product competitiveness to drive growth, with key products like Xin'ermei (Masitide injection) and Xinbile (Torecilizumab injection) becoming significant revenue contributors [2] Group 2 - The company's global innovation strategy continues to make breakthroughs, focusing on next-generation immunotherapy (IO) and antibody-drug conjugates (ADC) in oncology, as well as innovations in metabolism, cardiovascular, autoimmune, and ophthalmology fields [3] - The company aims to become an internationally leading biopharmaceutical company, supported by its ongoing clinical development and strategic advantages in flexible layout and efficient execution [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 信達生物製藥 INNOVENT BIOLOGICS, INC. （於開曼群島註冊成立的有限公司） 內幕消息公告－2025年全年及第四季度產品收入實現強勁增長 本公告由信達生物製藥（「本公司」，連同其附屬公司統稱「本集團」）根據香港聯合 交易所有限公司證券上市規則（「上市規則」）第13.09條及香港法例第571章證券及 期貨條例第XIVA部作出。 （股份代號：1801） 於2025年全年，本公司實現總產品收入約人民幣119億元，同比保持約45%的強 勁增長態勢。值得說明的是，於2025年第四季度，因六款新藥首次納入2026年國 家醫保目錄，本公司就按原價格分銷至渠道的產品，計提了相應金額的一次性庫 存補差。前述情況下，於2025年第四季度，本公司實現總產品收入約人民幣33億 元，同比增長超60%以上，依舊延續強勁增長勢頭。 2025年是本公司產品收入首次突破百億人民幣的里程碑之年，標誌着本公司「雙 輪驅動 ...

1. Report Industry Investment Rating No relevant content provided. 2. Core Viewpoints of the Report - Policy indicates that technology and artificial intelligence are entering an accelerated implementation phase, and the implementation of AI applications in leading technology companies is evident, supporting their performance growth [4]. - The Guozheng Hong Kong Stock Connect Technology Index focuses on leading technology companies in the Hong Kong stock market, has a high - weight concentration, and has relatively excellent historical performance. It also has differences and advantages compared with other Hong Kong technology indexes [4]. - The Huaxia Guozheng Hong Kong Stock Connect Technology ETF has increasing circulating shares and good on - site liquidity since its listing, and its fund managers have rich experience in managing ETF products [4]. 3. Summary According to Directory 3.1 Artificial Intelligence Accelerates Implementation, Supporting the Growth Momentum of Leading Technology Companies 3.1.1 Policy Points to Technology and Artificial Intelligence Entering an Accelerated Implementation Phase - On January 9, 2026, eight departments including the Ministry of Industry and Information Technology jointly issued the "Implementation Opinions on the Special Action of 'Artificial Intelligence + Manufacturing'". By 2027, China will promote the in - depth application of 3 - 5 general large - models in the manufacturing industry, form a large - scale application paradigm covering multiple industries, build 1000 high - level industrial intelligent agents, create 100 high - quality industrial data sets, and promote the implementation of 500 typical application scenarios [4][10]. 3.1.2 The Implementation of AI Applications in Leading Technology Companies is Evident, Supporting Performance Growth - Tencent Holdings: In the second quarter of 2025, AI - driven advertising technology upgrades significantly improved click - through rates and delivery efficiency, and marketing service revenue increased by about 20% year - on - year. The demand from enterprise customers for AI services has increased, and GPU leasing and API token usage have become new sources of revenue [13][14]. - Alibaba: In fiscal year 2025, the revenue growth rate of Alibaba Cloud's public cloud accelerated significantly, and the revenue of AI - related products has achieved triple - digit growth for seven consecutive quarters. The company clearly takes "AI + Cloud" as its core growth direction [14]. - Meituan: In 2025, it introduced AI technology and intelligent assistant tools in multiple scenarios, which helps optimize resource allocation and improve user and merchant experience [14]. - Xiaomi: By the end of 2024, the Xiaomi AIoT platform had connected 904 million devices (excluding smartphones and laptops), showing that AI has formed a real and continuous demand in the terminal [15]. 3.2 Guozheng Hong Kong Stock Connect Technology Index: Fully Covers the Hong Kong Technology Field and has High Offensive Elasticity 3.2.1 The Guozheng Hong Kong Stock Connect Technology Index Focuses on Leading Technology Companies in the Hong Kong Stock Market - The Guozheng Hong Kong Stock Connect Technology Index selects 30 listed company securities with large market capitalizations in the technology - related fields that are listed on the Hong Kong Stock Exchange and eligible for the Stock Connect program as index samples. As of December 31, 2025, the sum of the weights of the top five constituent stocks was 60.45%, and the sum of the weights of the top ten constituent stocks was 79.53%. Leading enterprises such as Tencent Holdings, Alibaba - W, Xiaomi Group - W, and Meituan - W have a weight of more than 10% [4][20]. 3.2.2 Comparison of the Guozheng Hong Kong Stock Connect Technology Index with Other Hong Kong Technology Indexes - In terms of the main industries covered by the index, the Guozheng Hong Kong Stock Connect Technology Index has a wider coverage. It includes the pharmaceutical industry compared with the Hang Seng Technology Index and adds hardware equipment, semiconductors, automobiles, and the pharmaceutical industry compared with the CSI Hong Kong Stock Connect Internet Index. In terms of the single - weight limit, it increases the weights of heavy - weight stocks compared with the Hang Seng Technology Index, making the index more elastic [4][28]. 3.2.3 The Guozheng Hong Kong Stock Connect Technology Index has Relatively Excellent Historical Performance - From 2019 to 2025, the annualized return of the Guozheng Hong Kong Stock Connect Technology Index was 12.98%, and the Sharpe ratio was 0.35, both significantly higher than those of the CSI Hong Kong Stock Connect Internet Index and the Hang Seng Technology Index. In annual return comparisons, it has greater elasticity in good market conditions and smaller decline amplitudes in poor market conditions [4][36]. 3.3 Analysis of the Investment Value of the Huaxia Guozheng Hong Kong Stock Connect Technology ETF 3.3.1 The Circulating Shares have been Continuously Increasing Since Listing and the On - site Liquidity is Good - Since its listing on September 3, 2025, the circulating shares of the Huaxia Guozheng Hong Kong Stock Connect Technology ETF have been increasing. As of January 27, 2026, the circulating shares increased to 3.059 billion, a 131.22% increase compared with the listing. Its on - site average daily turnover was 341 million yuan, and the highest daily turnover reached 792 million yuan [4][42][43]. 3.3.2 The Current Fund Managers' Managed ETF Products - The current fund managers of the Huaxia Guozheng Hong Kong Stock Connect Technology ETF are Mr. Xu Meng and Ms. Wang Xinwei. Taking Mr. Xu Meng as an example, as of January 27, 2026, he is currently managing 10 ETF products with a total scale of 222.98 billion yuan [49].

Core Viewpoint - The Hang Seng Index Company announced that the technology and biotechnology sectors will perform prominently in the Hong Kong stock market in 2025, with both the Hang Seng Technology Index and the Hang Seng Biotechnology Index achieving their best annual performance since their inception. In this context, the Hang Seng Dual Technology Index will be launched in January 2026, combining the constituents of both indices into a single index to highlight these two key themes [1][3]. Group 1: Performance of Indices - The Hang Seng Technology Index recorded a 23.5% increase in 2025, marking its highest annual growth since its launch in July 2020 [3]. - The Hang Seng Biotechnology Index achieved a remarkable 64.5% increase in 2025, representing its best annual performance since its inception in December 2019 [3]. - The strong performance of these indices is driven by structural factors and improvements in fundamentals [3]. Group 2: Industry Trends - The technology sector in China is a focal point, receiving clear and long-term policy support, with "significantly improving the level of technological self-reliance" being a major goal in China's 14th Five-Year Plan (2026-2030) [6]. - Artificial intelligence (AI) has become a key area of market focus, with Chinese AI models gaining global recognition [6]. - The Hang Seng Technology Index represents 30 of the largest technology companies listed in Hong Kong, focusing on areas such as smart technology, cloud computing, digital commerce, and fintech [6]. Group 3: Biotechnology Sector - The Chinese biotechnology sector has gained significant attention due to the increasing global recognition of innovative drugs developed in China, with the total value of outbound licensing transactions for innovative drugs reaching a record high of $136 billion in 2025 [7]. - This record transaction volume indicates a significant enhancement in the global competitiveness and technical capabilities of the Chinese biotechnology industry [7]. - The Hang Seng Biotechnology Index, which tracks the performance of the largest 30 biotechnology companies listed in Hong Kong, recorded a historic 64% annual increase in 2025 and continued to rise by 9% in January 2026 [8]. Group 4: Launch of the Hang Seng Dual Technology Index - The Hang Seng Dual Technology Index, launched on January 9, 2026, combines the two themes of technology and biotechnology, with a weight allocation of 75% to the Hang Seng Technology Index and 25% to the Hang Seng Biotechnology Index [12]. - The index recorded a 36% increase in 2025, with a continued upward trend into 2026, reflecting ongoing market interest in Chinese innovation themes [12]. - As of January 30, 2026, the index had a one-year annualized volatility of 34%, lower than the 35% and 40% of the Hang Seng Technology Index and Hang Seng Biotechnology Index, respectively, indicating a balanced risk profile [12].

Core Insights - Sequoia China, known for investing in innovative drugs and cutting-edge biotech, has made a surprising acquisition of the classic antibiotic Moxifloxacin (Avelox) from Bayer, establishing a new biopharmaceutical platform, Hangzhou Sanzhe Biopharmaceutical Co., Ltd. [1][2] - The acquisition is seen as a strategic move to leverage Moxifloxacin's existing market presence and cash flow while also aiming to introduce innovative products into the pipeline [5][8] Group 1: Acquisition Details - The acquisition involves Moxifloxacin, which has treated over 240 million patients globally, and includes key assets such as drug registration certificates and intellectual property [1][3] - Moxifloxacin was once a blockbuster drug for Bayer, generating nearly $1.2 billion in global sales in 2012, but has seen a decline in sales due to patent expiration and increased competition from generics [3][4] - In China, Bayer's market share for Moxifloxacin was approximately 34.75% in 2022, with local competitors capturing over 25% of the market [3] Group 2: Strategic Implications - Sequoia's acquisition reflects a shift from traditional VC investment strategies to a more private equity (PE) approach, focusing on optimizing and integrating mature businesses for stable cash flow [5][6] - The transaction is estimated to be between €160 million and €260 million, supported by financing from Shanghai Pudong Development Bank, indicating a leveraged buyout strategy [6][7] - The new platform, Sanzhe Biopharmaceutical, aims to operate Moxifloxacin as a "cash cow" while also serving as a foundation for introducing innovative products [7][8] Group 3: Leadership and Execution - Jin Xiaodong, a seasoned executive with extensive experience in multinational pharmaceutical companies, has been appointed to lead Sanzhe Biopharmaceutical, aligning with the company's dual strategy of managing mature products and seeking innovative assets [10][12] - Jin's background in commercializing mature products and his experience in strategic partnerships are seen as critical for the success of the new platform [11][12] Group 4: Challenges Ahead - Reviving Moxifloxacin in a competitive market, particularly under China's centralized procurement policies, presents a significant challenge for Sanzhe Biopharmaceutical [15] - The search for high-quality late-stage innovative assets is crucial, as the success of the strategy hinges on acquiring promising candidates in a competitive landscape [15][16] - Building an effective team and integrating the acquired global business with the new company's strategic goals will be essential for long-term success [16]

Core Insights - The report from Dongfang Securities highlights the significant commercial value of extrahepatic delivery technology, driven by MNCs' increasing interest and the rapid development of domestic companies in multi-target drugs and extrahepatic delivery platforms [1][2][3] Group 1: Market Dynamics - Frequent transactions in small nucleic acids indicate rising global recognition of domestic drugs, exemplified by recent strategic collaborations involving Shengyin Biotech and major pharmaceutical companies like Eli Lilly and Roche, which include upfront payments and milestone payments totaling up to $12 billion and $15 billion respectively [1] - MNCs are shifting focus from liver-targeted delivery technologies to extrahepatic delivery systems, targeting organs such as fat, muscle, central nervous system, heart, and kidneys, which could address significant unmet clinical needs [2] Group 2: Domestic Innovation - Domestic companies have accumulated substantial experience in chemical modifications and liver-targeted delivery technologies for small nucleic acids, covering high-value areas such as hyperlipidemia, hypertension, hepatitis B, and weight loss [3] - The proactive development of extrahepatic delivery platforms and multi-target small nucleic acid drug platforms positions domestic firms at the forefront globally, attracting MNCs' interest [3] Group 3: Investment Opportunities - Potential investment targets include companies such as Yuyuan Pharmaceutical, Frontier Biotech, Fuyuan Pharmaceutical, Chengdu Xian Dao, and others, which are positioned to benefit from the growing market for small nucleic acid drugs [4]

香港联交所最新资料显示，1月28日，摩根大通增持信达生物(01801)19.8871万股，每股作价83.829港 元，总金额约为1667.12万港元。增持后最新持股数目约为8678.41万股，最新持股比例为5%。 ...

智通财经APP获悉，香港联交所最新资料显示，1月28日，摩根大通增持信达生物(01801)19.8871万股， 每股作价83.829港元，总金额约为1667.12万港元。增持后最新持股数目约为8678.41万股，最新持股比 例为5%。 ...

Investment Rating - The industry investment rating is "Positive" (maintained) [6] Core Insights - The report highlights the significant commercial value of extrahepatic delivery technology for small nucleic acid drugs, which is expanding from liver diseases to multiple disease areas. Domestic companies are rapidly developing multi-target drugs and extrahepatic delivery platforms, which are expected to accelerate the release of potential clinical value [3][8] - The report emphasizes that multinational corporations (MNCs) are intensifying their focus on next-generation delivery platforms, moving from "liver validation" to "multi-organ expansion." This shift is crucial as it addresses unmet clinical needs in various tissues such as fat, muscle, central nervous system, heart, and kidneys [8] - The report indicates that 2026 is a pivotal year for small nucleic acid therapies, with domestic innovative drugs expected to become core assets for transactions. Domestic companies have accumulated rich experience in chemical modifications and liver-targeted delivery technologies, covering high-value areas such as hyperlipidemia, hypertension, hepatitis B, and weight loss [8] Summary by Sections Industry Overview - The report focuses on the pharmaceutical and biotechnology industry in China, specifically on small nucleic acid drugs and their evolving delivery technologies [5][6] Investment Recommendations and Targets - The report lists several investment targets, including: - YK Pharma (688658, Buy) - Hengrui Medicine (600276, Buy) - Xinda Biopharma (01801, Not Rated) - Other companies such as Chengdu XianDao (688222, Not Rated), Reborn Biotech (06938, Not Rated), and others [3]

港股通数据统计周报 2026.01.26-2026.02.01 | 分析师： | 蒋开来 | | --- | --- | | 中央编号： | BWL381 | | 联系电话： | 852-6430 1060 | | 邮箱： | jiangkl@cnzsqh.hk | 1 目录 2 l 港股通前十大净买入/卖出公司 l 港股通净买入/卖出行业分布 l 港股通前十大活跃个股 l 港股通与南下资金介绍 港股通前十大净买入/卖出公司 3 港股通本周前十大净买入公司（2026.01.26-2026.02.01） | 序号 | 证券代码 | 证券简称 | 行业 | 港股通持股变动数 | 净买入金额（亿元） | | --- | --- | --- | --- | --- | --- | | 1 | 9992.HK | 泡泡玛特 | 可选消费 | 13440803 | 30.05 | | 2 | 0700.HK | 腾讯控股 | 信息技术 | 4621172 | 28.00 | | 3 | 1810.HK | 小米集团-W | 信息技术 | 49988528 | 17.75 | | 4 | 2628.HK | 中国人寿 | ...